Josh advises the top teams at medical-products and device companies as they balance their portfolio and seek sources of growth. This work includes pursuing transactions, driving efficiency and effectiveness in R&D, and addressing opportunities to maximize the commercial value of core and emerging products.
Given the pressures to maintain organic growth in this sector, Josh helps executives establish a sustainable path for commercial operations, including unlocking market access and boosting commercial effectiveness. He also helps shape the business portfolio through acquisitions and R&D efficiency and effectiveness.
Examples of his recent client work include the following:
- developing a comprehensive portfolio strategy for a durable medical-equipment manufacturer, including a spin off and supporting M&A activity that resulted in $1 billion in value creation
- leading a commercial transformation for an orthopedic-device manufacturer, reversing a negative growth trend and resulting in a net increase in annual quarterly growth
- conducting full due diligence of a radioactive consumable-oncology product that featured complex supply-chain requirements as well as access hurdles to new markets
- designing a next-generation portfolio strategy for an implantable-cardiovascular-device company, architecting a product roadmap and commercial growth options supporting more than 10 percent growth
Interested in fostering cross-industry conversation, Josh has published articles addressing the dynamics that affect companies in the medical technology and device sectors. Before earning his MBA from MIT, with a focus on finance and healthcare, Josh spent 3 years working on advanced valuations and growth-strategy evaluations for the value-science team of a global consulting firm.